Ribociclib-Induced Vitiligo: A Case Report

Ribociclib-Induced Vitiligo: A Case Report

Bibliographic Details
Main Authors:	Nicolás Silvestre Torner, Antonio Aguilar Martínez, María José Echarri González, Sergio Tabbara Carrascosa, Jorge Román Sainz, Fernando Gruber Velasco
Format:	Article
Language:	English
Published:	Mattioli1885 2022-05-01
Series:	Dermatology Practical & Conceptual
Subjects:	vitiligo ribociclib selective cyclin-dependent kinase 4/6 inhibitors breast cancer adverse event
Online Access:	https://dpcj.org/index.php/dpc/article/view/1787

Similar Items

Case Report: Ribociclib-induced phototoxicity presented as dyschromia with subsequent bullae formation
by: Jyun-Yan Jhan, et al.
Published: (2023-08-01)

Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review
by: Sharaf B, et al.
Published: (2022-01-01)

Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function
by: S. F. Menshikova, et al.
Published: (2018-11-01)

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
by: Hasan Çağrı Yıldırım, et al.
Published: (2022-12-01)

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
by: Edessa D, et al.
Published: (2017-12-01)

Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells
by: Lei Zhang, et al.
Published: (2022-04-01)

Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response
by: Mariangela Pasqualoni, et al.
Published: (2023-03-01)

Ribociclib in 1st line HR+ breast cancer treatment
by: L G Zhukova, et al.
Published: (2018-06-01)

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
by: Cengiz Karacin, et al.
Published: (2023-02-01)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
by: Francesco Schettini, et al.
Published: (2018-12-01)

Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection
by: Parati MC, et al.
Published: (2022-04-01)

Etiopathogenesis and Emerging Methods for Treatment of Vitiligo
by: Tomasz Iwanowski, et al.
Published: (2023-06-01)

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
by: Navid Sobhani, et al.
Published: (2019-04-01)

Ribociclib + adjuvant hormone therapy in early breast cancer: prevention of recurrence. New opportunities. A review
by: Nikolai A. Ognerubov
Published: (2023-12-01)

Lappaol F regulates the cell cycle by activating CDKN1C/p57 in human colorectal cancer cells
by: Rui-Yi Yang, et al.
Published: (2023-12-01)

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
by: I. P. Ganshina, et al.
Published: (2019-06-01)

Ribociclib in newly diagnosed hepatitis B infection: A case report
by: Fabrizio Di Costanzo, et al.
Published: (2023-06-01)

Ribociclib in patient with hormone-positive HER2-negative breast cancer with brain metastases: a case report
by: N. S. Prizova, et al.
Published: (2022-06-01)

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
by: Zvonimir Mlinarić, et al.
Published: (2022-11-01)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
by: Iorfida M, et al.
Published: (2020-03-01)

Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
by: Shan Gao, et al.
Published: (2023-07-01)

Multiple cutaneous melanomas associated with gastric and brain metastases
by: Lara Caroline Grander, et al.
Published: (2016-10-01)

Cyclin-dependent kinase inhibitors: efficacy and safety
by: I. B. Kononenko, et al.
Published: (2019-06-01)

Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence
by: Wedad H. Alotaibi, et al.
Published: (2022-08-01)

Ribociclib-induced liver injury: a case report
by: Sofia Schaeffer, et al.
Published: (2023-12-01)

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
by: Lu Turković, et al.
Published: (2022-05-01)

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial
by: Javier Salvador Bofill, et al.
Published: (2022-12-01)

Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study
by: Kadir Eser, et al.
Published: (2022-05-01)

Identification of abemaciclib derivatives targeting cyclin-dependent kinase 4 and 6 using molecular dynamics, binding free energy calculation, synthesis, and pharmacological evaluation
by: Yanting Zhou, et al.
Published: (2023-05-01)

Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial
by: Paul Cottu, et al.
Published: (2022-04-01)

Cyclin B Export to the Cytoplasm via the Nup62 Subcomplex and Subsequent Rapid Nuclear Import Are Required for the Initiation of <i>Drosophila</i> Male Meiosis
by: Kanta Yamazoe, et al.
Published: (2023-11-01)

Ribociclib-induced acute kidney injury in patients with advanced-stage breast cancer: A case series and literature review
by: Maissoune Hajir, et al.
Published: (2023-09-01)

Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER+HER2−Rb wild-type and knock-down in breast cancer cell lines
by: Oliviero Marinelli, et al.
Published: (2020-11-01)

Binding selectivity-dependent molecular mechanism of inhibitors towards CDK2 and CDK6 investigated by multiple short molecular dynamics and free energy landscapes
by: Lifei Wang, et al.
Published: (2023-12-01)

Effect of vorinostat on INK4 family and HDACs 1, 2, and 3 in pancreatic cancer and hepatocellular carcinoma
by: Masumeh Sanaei, et al.
Published: (2021-01-01)

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
by: P. Neven, et al.
Published: (2023-08-01)

Exploring cell cycle-mediated regulations of glycolysis in budding yeast
by: Yanfei Zhang, et al.
Published: (2023-10-01)

Targeting Protein-Protein Interactions to Inhibit Cyclin-Dependent Kinases
by: Mark Klein
Published: (2023-03-01)

Expression of cyclooxygenase-2(COX-2) and cyclin dependent kinase 1B (CDKN1B/p27Kip1⁯) in human prostatet adenocarcinoma
by: Md Roduan, Mohd Rohaizad
Published: (2011)

Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior
by: Alan Umfress, et al.
Published: (2022-05-01)